Beta Bionics BBNX 深 滬
等待開盤 09-18 09:30:00 美东时间
21.43
-0.750
-3.38%
華盛通- 最 高22.66
- 今 開22.46
- 成交量 309.09万股
- 最 低 20.39
- 昨 收 22.18
- 總市值 9.64亿
- 52周最高 32.71
- 市盈率 靜 --
- 換手率 6.87%
- 52周最低 8.80
- 委 比 98.12%
- 總股本 4498.97万
- 歷史最高 32.71
- 量 比 1.25
- 振 幅 10.23%
- 歷史最低 8.80
- 每 手 1
- 風險率 6.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | LITE升近10%，Credo升逾7%，Ciena上调长期增长目标提振光通信板块；CIFR升逾10%，AI数据中心转型预期升温；FTAI升近8%
LITE升近10%，Credo升逾7%，Ciena上调长期增长目标提振光通信板块；CIFR升逾10%，AI数据中心转型预期升温；FTAI升近8%，宣布5亿美元股份回购计划>>
09-17 18:46
LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Nasdaq Composite gaining around 150 points on Wednesday. Shares of LuxExperience BV-ADR (NYSE:LUXE) rose sharply after the company reported fourth-quarter results. LuxExperience reported quarterly losses of 21 cents per share which missed the analyst consensus estima...
09-16 21:57
Beta Bionics shares fall as company prices $150M stock offering at $17.25/share
Beta Bionics (BBNX) priced an underwritten public offering of 7,652,175 common shares at $17.25/share plus pre-funded warrants for 1,043,484 shares at $17.2499 each. Gross proceeds are expected to be ...
09-16 17:43
美股大行评级 | 巴克莱大幅升Strategy目标价至160美元！康宁遭看淡至180美元，较现价仍溢价25%
今日重点评级关注：HC Wainwright & Co.：上调Cardiff Oncology评级至"买入"，目标价9美元；古根海姆：维持Inventiva"买入"评级，目标价从11美元升至14美元
09-16 16:10
Beta Bionics, Inc. (BBNX) Receives a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Jonathan Block maintained a Buy rating on Beta Bionics,...
09-16 10:05
Senseonics Partners With Beta Bionics To Integrate Its Eversense 365 CGM With Beta Bionics’ iLet Bionic Pancreas Automated Insulin Delivery System
The companies are collaborating to integrate Eversense® 365 CGM with Beta Bionics’ iLet® Bionic Pancreas automated insulin delivery (AID) system designed to simplify diabetes management. The integrated device will aim to provide people with diabetes a world-class, truly differentiated AID experience...
09-14 19:05
Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas
Senseonics and Beta Bionics collaborate to integrate Eversense 365 CGM with iLet Bionic Pancreas for enhanced diabetes management. The combined system aims to simplify insulin delivery and glucose monitoring, offering a year-long sensing solution without carb counting. Commercial launch planned for Q4 2026.
09-14 11:00
William Blair Initiates Coverage On Beta Bionics with Market Perform Rating
William Blair analyst Steven Lichtman initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Market Perform rating.
08-22 04:15
Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics
On Friday, William Blair initiated coverage on Tandem Diabetes Care Inc. (NASDAQ:TNDM) and Beta Bionics Inc (NASDAQ:BBNX), noting that both companies are advancing initiatives to play in faster-growing segments of the insulin pump market. Both companies have the potential to benefit from market expa...
08-22 01:31
Beta Bionics Affirms FY2026 Sales Guidance of $131.000M-$136.000M vs $133.305M Est
Beta Bionics (NASDAQ:BBNX) affirms FY2026 sales outlook from $131.000 million-$136.000 million to $131.000 million-$136.000 million vs $133.305 million estimate.
07-30 04:03
